Evox Therapeutics Ltd

Evox Therapeutics Ltd company information, Employees & Contact Information

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

Company Details

Employees
45
Founded
-
Address
Oxford Science Park, Medwar Center,united Kingdom
Phone
+44 (0) 1865 819140
Email
en****@****ics.com
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
Oxford, England
Looking for a particular Evox Therapeutics Ltd employee's phone or email?

Evox Therapeutics Ltd Questions

News

Exosome Therapeutics Market Size to Hit USD 4,020.75 Thousand by 2034 - Precedence Research

Exosome Therapeutics Market Size to Hit USD 4,020.75 Thousand by 2034 Precedence Research

Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive Officer - GlobeNewswire

Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive Officer GlobeNewswire

Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery - BioInformant

Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery BioInformant

Evox Therapeutics completes $95.4M Series C - Drug Delivery Business

Evox Therapeutics completes $95.4M Series C Drug Delivery Business

Evox Therapeutics reaches gene therapy agreement - PharmaTimes

Evox Therapeutics reaches gene therapy agreement PharmaTimes

Evox Therapeutics - The Pharma Letter

Evox Therapeutics The Pharma Letter

Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases - Labiotech.eu

Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases Labiotech.eu

Evox Therapeutics reels in $95M to propel exosome-based pipeline - Fierce Biotech

Evox Therapeutics reels in $95M to propel exosome-based pipeline Fierce Biotech

Lilly pens antisense neuro pact with Evox Therapeutics - Fierce Biotech

Lilly pens antisense neuro pact with Evox Therapeutics Fierce Biotech

Top Evox Therapeutics Ltd Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant